Target intelligence / Profile preview

Mucin glycoprotein in the tear film

Molecular classification
Other, Secreted glycoprotein, Membrane-associated glycoprotein
01

Overview

Mucin glycoproteins in the tear film are a diverse and essential group of heavily O-glycosylated proteins secreted by goblet cells (mainly MUC5AC, MUC2, MUC5B) and presented on the apical surface of corneal and conjunctival epithelia (mainly MUC1, MUC4, MUC16). These molecules maintain ocular surface hydration, prevent pathogen binding, provide lubrication to minimize mechanical damage from blinking, and regulate both barrier properties and cell signaling. Disruption or deficiency of tear film mucins is strongly associated with dry eye symptoms, increased surface friction, tear instability, and increased infection risk. While the mucin layer is essential for healthy vision and ocular surface defense, it is a complex mixture rather than a single pharmacological target, necessitating precise nomenclature for drug development and research.

Other names
Ocular surface mucinsTear film mucinsMucin family members in tear filmGlycocalyx mucins
02

Mechanism of action

Reduction of mucin disulfide bonding (NAC); Augmentation of mucin/tear secretion (experimental compounds, not approved); Restoration of mucin-like lubrication (recombinant lubricin/mucin analogs); Indirect stabilization or replenishment of tear film mucins (artificial tears with mucinomimetic properties)

03

Biological functions

Maintenance of ocular surface hydration and wettabilityBarrier function against pathogensLubrication of ocular surfacePrevention of cell adhesion (anti-adhesive)Scavenging pathogens and debrisRegulation of epithelial cell signaling and growthMinimizing friction from blinkingFormation of tear film structure and stability
04

Disease associations

Dry eye diseaseOcular surface inflammationInfectionOther
05

Safety considerations

Difficult to selectively target individual mucin family members pharmacologicallyAltering mucins may disrupt the ocular defense barrier, increasing susceptibility to injury/infectionOverly aggressive mucolytic therapy (e.g., high-dose NAC) can worsen surface desiccation or damage epithelial glycocalyxHeterogeneity among patients in mucin expression or shedding complicates biomarker interpretation and therapy design
06

Interacting drugs

N-acetylcysteine

2 more in the full profile.

07

Biomarkers

MUC5AC concentrations in tearsMembrane-associated mucin (e.g., MUC16) sheddingTear breakup time (TBUT)

Beyond the preview

Go deeper on Mucin glycoprotein in the tear film.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin glycoprotein in the tear film.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call